Armada Hoffler Properties is a holding company and conducts substantially all of its operations through Armada Hoffler, L.P. The company is a real estate company engaged in developing, building, owning and managing institutional-grade office, retail and multifamily properties primarily throughout the Mid-Atlantic and Southeastern U.S. In addition to the ownership of its operating property portfolio, the company develops and builds properties for its own account and through joint ventures between the company and unaffiliated partners and also invests in development projects through mezzanine lending arrangements. The company also provides general contracting services to third parties.

Farmer Bros. is a coffee roaster, wholesaler and distributor of coffee, tea and culinary products. The company's products are manufactured under supply agreements, under its owned brands, as well as under private labels on behalf of certain customers. The company's product categories consist of the following: a line of roast and ground coffee, including organic, Direct Trade, Project D.I.R.E.C.T.? and other offerings; frozen liquid coffee; flavored and unflavored iced and hot teas; culinary products and coffee-related products; spices; and other beverages. The company's primary brands include Farmer Brothers?, Artisan Collection by Farmer Brothers?, Superior?, Metropolitan?, China Mist? and Boyds?.

JELD-WEN Holding is a holding company. Through its subsidiaries, the company is a door and window manufacturer. The company designs, produces, and distributes a range of interior and exterior doors, wood, vinyl, and aluminum windows, and related products for use in the construction and repair and remodel of residential homes and, to a lesser extent, non-residential buildings. The company markets its products under the JELD-WEN brand, along with several brands such as Swedoor and DANA in Europe and Corinthian, Stegbar, and Trend in Australia. The company's customers include wholesale distributors and retailers as well as individual contractors and consumers. The company has three segments: North America, Europe, and Australasia.

Scholar Rock is a biopharmaceutical company. The company's primary product candidate, SRK-015, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. The company's second product candidate is SRK-181 and is being developed for the treatment of cancers resistant to checkpoint blockade therapies, such as anti-PD1 antibodies. The company's third antibody program targets the signaling of bone morphogenetic protein 6, another member of the TGF? superfamily, which is involved in a set of biological processes in various parts of the body.